"NASH Treatment with DHEA"
Kolkata, India – Scientists at the Sanjay Gandhi Postgraduate Institute of Medical Sciences (SGPGIMS) have revealed a groundbreaking new approach to treating Non-Alcoholic Steatohepatitis (NASH), a severe liver disease that affects millions worldwide.
The innovative research, led by Rohit A Sinha, a scientist and associate professor in the endocrinology department, along with his teams Sana Raza and Pratima Gupta, found that naturally occurring hormone dehydroepiandrosterone (DHEA) helps reduce liver damage caused by NASH by removing harmful fats from liver cells, decreasing inflammation, and preventing further liver damage. This is significant news for healthcare professionals and the general public, providing a new hope for those suffering from NASH.
NASH Varnished as a "Silent Epidemic"
According to a Union health ministry document, NASH is the most dangerous form of Non-Alcoholic Fatty Liver Disease (NAFLD). NAFLD affects around 9% to 32% of the community, depending on various factors such as age, gender, place of residence, and socioeconomic status. The alarming fact is that 20% of NAFLD patients develop NASH, posing a significant risk to public health.
Key Research Findings
In animals, researchers administered DHEA to induce NASH in a NASH model, where the experiment showed a reduction of 80% of liver damage in 80% of the samples. Similar results were observed in human liver cells, where the fat percentage decreased up to 80% when DHEA was introduced. This promising finding opens the door for future clinical trials and potentially effective DHEA-based treatments for NASH.
Next Steps
Following animal and cellular studies, Sinha, along with his team, currently plans to transition into clinical trials.
Published On: June 3, 2025, at 11:38 AM IST
Subscribe to ETHealthworld Newsletters to stay informed!
Join the community of 2M+ industry professionals Subscribe to our newsletter to get latest insights & analysis.
